Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-12-04 Legal Proceedings Report
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항(마이크로바이옴 면역항암 치료제 GEN-001의 담도암 환자 대상 국내 제2상 임상시험계획 (IND) 변경승인신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Genome & Company) regarding a correction to a previously filed 'Major Management Matter' (투자판단 관련 주요경영사항) concerning a clinical trial (IND) amendment for a microbiome-based cancer therapy. Since this document is a formal regulatory disclosure filed with the exchange (KRX) regarding clinical trial updates and does not fit into specific categories like financial reports or board changes, it is classified as a general regulatory filing.
2023-12-04 Korean
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인)(진행성 불응성 담도암 환자를 대상으로 펨브롤리주맙과 병용 투여 시 GEN-001의 안전성 및 유효성을 평가하는 제2상 임상시험)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Genome & Company) regarding a 'Correction Report' (정정신고) for a previously disclosed clinical trial plan (IND) amendment. It details specific changes to statistical analysis methods and clinical trial parameters. Since it is a formal regulatory disclosure regarding material business operations (clinical trials) filed with the exchange, it falls under the 'Regulatory Filings' category.
2023-12-04 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for an upcoming Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting results, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure of corporate action, it fits best under the RNS category.
2023-11-17 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for the company 'Genome & Company'. It outlines the date, time, location, and the agenda items (specifically a proposal to amend the articles of incorporation). This type of document is a standard proxy solicitation or meeting notice sent to shareholders to inform them of an upcoming meeting and the matters to be voted upon. Given the provided categories, 'PSI' (Proxy Solicitation & Information Statement) is the most accurate classification for a notice of a shareholder meeting and its agenda.
2023-11-17 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Genome & Company' (지놈앤컴퍼니) covering the period from January 1, 2023, to September 30, 2023. It contains detailed corporate information, business descriptions, capital changes, and financial disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
전환가액의조정(제1회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) issued by Genome & Company. It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This falls under capital structure changes related to debt-to-equity instruments, which is best classified as a Capital/Financing Update.
2023-11-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.